Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Mar 2011
Randomized Controlled Trial Multicenter StudyRandomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data.
Limited therapeutic options exist for severe gastroparesis, where severe nausea and vomiting can lead to weight loss, dehydration and malnutrition due to inadequate caloric and fluid intake. TZP-101 (ulimorelin) is a ghrelin receptor agonist that accelerates gastric emptying and improves upper gastrointestinal symptoms in diabetic patients with gastroparesis. ⋯ TZP-101 substantially reduced the frequency and severity of nausea and vomiting as well as overall gastroparesis symptoms. The results are consistent with gastrointestinal motility effects of TZP-101, supporting further investigation of TZP-101 in the management of severe gastroparesis.
-
Aliment. Pharmacol. Ther. · Mar 2011
Endogenously released opioids mediate meal-induced gastric relaxation via peripheral mu-opioid receptors.
The centrally acting mu-opioid receptor antagonist naloxone inhibits meal-induced gastric accommodation. ⋯ These results indicate that endogenous opioids mediate gastric accommodation and satiation via peripheral mu-opioid receptors. Effects were less pronounced after naloxone treatment, which indicates that centrally involved mu-opioid receptors mediate an opposing effect.